The top blockbuster drug for 2016 was based on the techniques by Professor Sir Gregory Winter; his latest Cambridge company, Bicycle Therapeutics, has gained £40 million from investors including patient capital from Cambridge Innovation Capital.

Bicycle Therapeutics was co-founded by Professor Sir Gregory Winter, pioneer of therapeutic monoclonal antibodies and a member of CIC’s Advisory Panel.

His work created a step change in the treatment of cancer and immune disorder and, as a result, many of the world’s blockbuster pharmaceutical drugs are based on the techniques he developed.

"Bicycles are a new type of therapeutic that combine the best features of current approaches. They can penetrate tumours like small molecules, are specific like antibodies and are rapidly excreted like peptides, making them easy to administer and potentially avoiding the side-effects and limitations seen in the current treatments.

“The pre-clinical studies to date show Bicycles have an attractive profile. The next big step is to take this into humans and if they show the same characteristics this will be very exciting; offering a new choice of therapeutic.

"Bicycle Therapeutics is an ambitious company, with a world-class team, that has all the ingredients for another Cambridge success story.

New class of therapeutic

Bicycle Therapeutics is pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform. Proceeds of the fundraising will be used to further the development of multiple drug candidates, including Bicycle Therapeutics’ lead molecule, BT1718, a first-in-class drug for cancers with high unmet need.

As part of this financing Michael Anstey, Investment Director at CIC, is joining Bicycle Therapeutics’ Board of Directors.

Best of both worlds

Bicycle Therapeutics is developing novel first-in-class medicines based on its Bicycle product platform. Bicycles can combine the properties of several therapeutic entities in a single modality: exhibiting the affinity and selective pharmacology associated with antibodies; the distribution kinetics of small molecules, allowing rapid tumour penetration; and the “tuneable” pharmacokinetic half-life and renal clearance of peptides.

It is expected to enter the clinic in 2017 in partnership with Cancer Research UK.

The Series B financing round will also fund additional pipeline programmes through early clinical development, the first of which will be selected in the second half of 2017.

"This financing represents an important validation of our approach, while providing Bicycle Therapeutics with the resources to continue to advance our pipeline and translate our bicyclic peptide technology into important new treatment options for patients,” said Dr Kevin Lee, Bicycle Therapeutics’ CEO.

“We are grateful for the strong support from our investors as we move BT1718 rapidly towards the clinic and continue to advance our preclinical programmes, including toxin drug conjugates and immune modulators to treat cancer and other debilitating diseases.”